



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 03 Dec 2018 (#36)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- National Institute of Allergy and Infectious Diseases (NIAID) sets [Interim Paylines](#) to reflect conservative estimates of how many awards NIAID can afford to fund in fiscal year (FY) 2019. Most years, NIAID is able to adjust the paylines upward once they have a better sense of how many applications they will receive for the fiscal year; that process is explained at [NIAID Paylines and Budget Information Changes Throughout the Year](#).
- [Grantees: Are you able to add an Opioids component to your Research?](#) NIAID is leading a project for the [NIH HEAL Initiative](#) to develop vaccines that target opioids to help treat people with an opioid use disorder. Thus, the Institute will provide one-year administrative supplements to existing grants and contracts to support activities to develop vaccines that target opioids.
- NIH seeks feedback on the definition of Scientific Data and general requirements for Data Management and Sharing Plans. [Share Your Thoughts on a Future Policy for Data Management and Sharing](#)
- [Understanding Age in the NIH Portfolio: Implementation of the NIH Inclusion Across the Lifespan Policy](#) announced a revision to its Inclusion of Children Policy to expand the policy to individuals of all ages. The revised policy, now called the Inclusion Across the Lifespan policy, requires individuals of all ages (including children and older adults) be included in clinical research studies unless there are scientific or ethical reasons to exclude them.

1. Medications Development for the Treatment of Alcohol Use Disorder (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AA-19-005\)](#)

Type: U01

Application Due Date: February 11, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds through the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will support animal studies to prove efficacy if the candidate compound is patentable and has a plausible path to commercialization. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.

Budget: NIAAA intends to commit \$3.0M in FY 2019 to fund 4 awards. No more than \$1.0 million direct costs per year may be requested for applications proposing IND enabling studies. No more than \$500,000 direct costs per year for applications that propose only Phase 2 human laboratory and proof-of-concept clinical trials. No more than \$1.5 million may be requested by applications that proposing both IND enabling studies and Phase 2 human laboratory and proof-of-concept clinical trials. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Single-Cell Multi-Omics of HIV Persistence (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-18-053\)](#)

Type: R01

Application Due Date: March 13, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) will support basic science research to address outstanding questions in HIV latency and persistence by leveraging state-of-the-art single-cell multi-omics approaches. The goal is to interrogate HIV persistence with high molecular detail and resolution to better understand HIV persistence at the single-cell level. Emphasis will be on multi-omics or multiplex approaches integrating cutting-edge single-cell analysis technologies.

Budget: Issuing IC and partner components intend to commit an estimated total of \$2.25 million to fund 3-4 awards. Application budgets should be appropriate for the scope of work proposed and may not exceed a maximum of \$499,999 per year in direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Processing and Presentation of Non-Conventional MHC Ligands (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-067\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21 - The combined direct costs budget for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

4. Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-068\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases. NIAID has made significant investments in the generation of data to better inform our understanding of infectious diseases, their progression, risk and severity and, treatment and prevention. In particular, the omics-related programs have generated high-throughput genomic, proteomics, integrated "omics" data sets, and other related resources to the scientific community to further basic and applied research in infectious diseases. These are available via the Bioinformatics Resource Centers (BRCs) - <https://www.niaid.nih.gov/research/bioinformatics-resource-centers> - for the scientific community to better enable the use of open access data.

Budget: Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is 2 years.

5. Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-069\)](#)

Type: R03

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

Budget: The combined budget for direct costs for the two year project period may not exceed \$200,000. A project duration of up to two years may be requested.

6. Research on Current Topics in Alzheimer's Disease and Its Related Dementias (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-070\)](#)
[\(PAR-19-071\)](#)

Type: R01
R21

Application Due Date: March 11, 2019; July 9, 2019; November 12, 2019; March 11, 2020; July 9, 2020; November 12, 2020; March 11, 2021; July 9, 2021; and November 12, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Christa* • Tel: 9838 • Email: cde.vries@sun.ac.za